US · EVOK
Evoke Pharma, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Solana Beach, CA 92075
- Website
- evokepharma.com
Price · as of 2024-12-31
—
Market cap 16.66M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $44.86 | — |
| Intrinsic Value(DCF) | $424,717.53 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | $1,425.60 | ||||
| 2014 | $960.48 | ||||
| 2015 | $666.72 | ||||
| 2016 | $449.28 | ||||
| 2017 | $285.12 | ||||
| 2018 | $182.88 | ||||
| 2019 | $192.96 | ||||
| 2020 | $352.80 | ||||
| 2021 | $74.16 | $1,714.75 | $104.69 | $0.00 | $0.00 |
| 2022 | $43.20 | $2,147.93 | $239.48 | $0.00 | $0.00 |
| 2023 | $8.40 | $1,050.31 | $45,859,887.03 | $0.00 | $0.00 |
| 2024 | $3.88 | $44.86 | $6,681,695.98 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Evoke Pharma, Inc.'s (EVOK) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $44.86
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$424,717.53
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| EVOK | Evoke Pharma, Inc. | $10.69 | 16.66M | +320% | +3,972,936% | — | — | -1.38 | 1.05 | 0.72 | 0.22 | — | 1.05 | 96.52% | -50.77% | -52.22% | -240.09% | 280.01% | -43.54% | 0.73 | -10.38 | 1.66 | 1.54 | 1.74 | -8995.00% | 9784.00% | 950.00% | -73.85% | -0.53 | 293.71% | 0.00% | 0.00% | 117.66% | 0.20 | 0.19 | -0.10 | -9.79 |
| ADIL | Adial Pharmaceuticals, In… | $0.33 | 7.26M | — | — | — | — | -1.06 | 3.43 | — | -1.23 | — | 3.43 | 0.00% | — | — | -323.80% | -1052.66% | -269.86% | 0.00 | — | 4.16 | 3.84 | 0.45 | -8695.00% | — | — | -49.65% | -7.09 | -879.58% | 0.00% | 0.00% | 6.62% | -1.23 | -1.47 | — | -18.87 |
| BFRI | Biofrontera Inc. | $1.09 | 11.63M | +13,983% | -66% | — | — | -0.29 | 1.14 | 0.14 | -0.28 | — | 1.15 | 50.12% | -46.14% | -47.61% | -384.98% | -281.81% | -70.99% | 1.11 | -8.17 | 1.72 | 0.93 | 0.07 | -7527.00% | 949.00% | -5851.00% | -203.55% | -0.85 | -169.15% | 0.00% | 0.00% | 99.29% | -0.24 | -0.40 | 0.11 | -7.68 |
| BMRA | Biomerica, Inc. | $2.58 | 7.4M | +7,094% | -52% | — | — | -1.44 | 1.74 | 1.35 | -1.10 | -0.29 | 1.84 | 9.38% | -96.72% | -93.64% | -92.99% | -191.32% | -65.44% | 0.11 | — | 2.80 | 1.80 | 0.41 | 50000.00% | -192.00% | -2918.00% | -54.28% | -2.21 | -144.43% | 0.00% | 0.00% | 0.00% | -1.01 | -1.34 | 0.98 | -11.52 |
| MHUA | Meihua International Medi… | $0.24 | 7.52M | +23,099% | +53% | +3,205% | +1,234% | 0.81 | 0.06 | 0.09 | 0.05 | — | 0.06 | 34.36% | 14.77% | 11.19% | 7.10% | 7.91% | 6.05% | 0.05 | 9.50 | 5.26 | 4.80 | -0.51 | -1837.00% | -19.00% | -70159.00% | 165.58% | 0.54 | 10.08% | 0.00% | 0.00% | 2.28% | 0.05 | 0.05 | 0.01 | 2.51 |
| NRSN | NeuroSense Therapeutics L… | $1.05 | 25.87M | — | — | — | — | -2.06 | 8.14 | — | -1.79 | — | 8.14 | 0.00% | — | — | -2880.11% | 388.77% | -263.45% | 0.03 | -31.84 | 2.21 | 1.78 | 0.33 | -3373.00% | — | 2094.00% | -48.23% | -5.09 | 398.04% | 0.00% | 0.00% | 3.84% | -1.79 | -1.75 | — | -11.40 |
| SBFM | Sunshine Biopharma, Inc. | $1.77 | 8.06M | +2,910% | +44,030,507% | — | — | -0.33 | 0.07 | 0.05 | 1.37 | — | 0.08 | 30.60% | -16.67% | -14.72% | -22.97% | -54.65% | -17.73% | 0.04 | -662.41 | 4.11 | 2.15 | 1.69 | -9792.00% | 4475.00% | 5530.00% | -885.54% | -1.98 | -146.04% | 0.00% | 0.00% | 187.20% | 1.21 | 0.48 | -0.20 | -1.74 |
| SNOA | Sonoma Pharmaceuticals, I… | $3.76 | 6.2M | +26,836% | -65% | — | — | -1.19 | 0.93 | 0.29 | 0.27 | — | 0.93 | 38.25% | -25.97% | -24.20% | -65.55% | -250.76% | -24.32% | 0.07 | — | 3.09 | 2.23 | 1.42 | -4756.00% | 1219.00% | -9304.00% | -4.08% | -0.02 | -11.36% | 0.00% | 0.00% | 61.89% | 0.26 | 5.65 | -0.07 | -19.06 |
| SSKN | STRATA Skin Sciences, Inc… | $1.70 | 7.09M | +3,178% | -40% | — | — | -9.66 | 19.60 | 2.90 | -37.52 | — | -32.12 | 56.85% | -27.58% | -30.05% | -114.22% | -51.01% | -25.80% | 3.31 | -4.39 | 1.13 | 0.86 | -3.23 | -1613.00% | 61.00% | -7385.00% | -1.49% | 0.01 | -8.11% | 0.00% | 0.00% | 0.00% | -11.52 | -73.65 | 3.18 | -7.58 |
About Evoke Pharma, Inc.
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
- CEO
- Matthew J. D'Onofrio MBA
- Employees
- 3
- Beta
- -0.03
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($424,717.53 ÷ —) − 1 = — (DCF, example).